

## Autoimmune Liver Disease Panels

### Autoimmune Hepatitis

(AIH)


### Primary biliary cholangiitis (cirrhosis)

(PBC)

### Primary Sclerosing Cholangiitis

(PSC)

Overlap Syndromes can occur



#### Autoimmune hepatitis (AIH) with subtypes AIH type 1 and AIH type 2

- Female Predominance (>75%).
- Can progress to liver cirrhosis and hepatocellular carcinoma.
- Up to 90% AIH patients show pathological titers of at least one AAb.
- AAb against cell nuclei (ANA), especially those that produce a homogeneous pattern.
- AAb against smooth muscle (ASMA, important target antigen F-actin).
- AAb against dsDNA.
- AAb against liver-kidney microsomes (LKM-1; target antigen cytochrome P450 IID6).
- AAb against cytosolic liver antigen type 1 (LC-1; target antigen formiminotransferase cyclodeaminase, FTCD).
- AAb against granulocytes (p-ANCA, perinuclear antineutrophil cytoplasmic antibody).

#### Primary biliary cholangiitis (cirrhosis) (PBC)

Chronic non-suppurative destructive cholangiitis with progressive inflammatory destruction of the small biliary ducts and liver cirrhosis.

##### Criteria for diagnosis :

- Biochemical markers of cholestasis
- Histopathology
- Presence of AAbs (AMA/ANA)

#### Primary sclerosing cholangiitis (PSC)

Primary sclerosing cholangiitis is chronic fibro-obliterative inflammation of the intra and extra hepatic bile ducts.

##### Criteria for diagnosis :

- Biochemical makers
- Presence of p-ANCA AAbs

# Immunoblot



AMA-M2

LKM-1






LC-1

SLA/LP

Control

| Auto-immunolog<br>Test marker | Prevalence<br>AIH                              | Prevalence<br>PBC | Prevalence<br>PSC | Prevalence<br>Overlap syndrome |
|-------------------------------|--|-------------------|-------------------|--------------------------------|
| AMA                           | —  | 85% – 95%         | <5%               | 30% – 96%                      |
| LKM-1                         | 3% – 5% (AIH)<br>70% (AIH-type 2)              | —                 | —                 | —                              |
| LC-1                          | 10% AIH<br>35% (AIH-type 2)                    | —                 | —                 | —                              |
| SLA/LP                        | 15%–30%<br>(Europe, North America)<br>7% Japan | —                 | —                 | <10%                           |

# Immunofluorescence



**International Consensus Guidelines recommend all Sera are first tested by IIF and subsequently by ELISA**

## AG ADVANTAGE

Carrying forward Dr. Ajit Golwilkar's Legacy of over 4 decades

State-Of-The-Art Pathology Laboratory & Diagnostic Centre Spread Across 16000 sq. ft.

NABL Accredited as per ISO 15189:2012, Certificate Number : MC – 3143

Skilled and Experienced Pathologists, Microbiologists & Technical Team

Fully Automated & Barcoded Process, Wide Test Menu

Network of over 50 Collection Centres

Services at your Doorstep: Home Collection by our Expert Phlebotomists & Online Report System

Wellness Centre at Main Lab, Bhandarkar Road, well equipped with ECG, TMT / Stress Test, 2D Echo, X-Ray, USG facilities under one roof, with prior appointment

Carrying forward  
Dr. Ajit Golwilkar's  
**legacy**  
of over  
**Four  
Decades**



**Main Laboratory : A.G Diagnostics Pvt. Ltd. Nayantara, Bhandarkar Road, Pune 411004. INDIA.**

**Tel.: +91 20 6763 6763 / +91 20 2565 1400 | info@agdiagnostics.com | www.agdiagnostics.com**